These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 29141650)

  • 21. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone.
    Sullivan LE; Botsko M; Cunningham CO; O'Connor PG; Hersh D; Mitty J; Lum PJ; Schottenfeld RS; Fiellin DA;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S54-61. PubMed ID: 21317595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with non-adherence to Buprenorphine-naloxone among opioid dependent African-Americans: A retrospective chart review.
    Kumari S; Manalai P; Leong S; Wooditch A; Malik M; Lawson WB
    Am J Addict; 2016 Mar; 25(2):110-7. PubMed ID: 26749158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of an integrated digital health intervention to promote engagement in and adherence to medication for opioid use disorder.
    Langdon KJ; Ramsey S; Scherzer C; Carey K; Ranney ML; Rich J
    Addict Sci Clin Pract; 2020 Apr; 15(1):16. PubMed ID: 32349790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders.
    Romero-Gonzalez M; Shahanaghi A; DiGirolamo GJ; Gonzalez G
    Am J Addict; 2017 Dec; 26(8):838-844. PubMed ID: 29143399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
    Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
    J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictability of buprenorphine-naloxone treatment retention: A multi-site analysis combining electronic health records and machine learning.
    Nateghi Haredasht F; Fouladvand S; Tate S; Chan MM; Yeow JJL; Griffiths K; Lopez I; Bertz JW; Miner AS; Hernandez-Boussard T; Chen CA; Deng H; Humphreys K; Lembke A; Vance LA; Chen JH
    Addiction; 2024 Oct; 119(10):1792-1802. PubMed ID: 38923168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
    Manhapra A; Agbese E; Leslie DL; Rosenheck RA
    Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of buprenorphine/naloxone maintenance treatment on sexual dysfunction, sleep and weight in opioid use disorder patients.
    Baykara S; Alban K
    Psychiatry Res; 2019 Feb; 272():450-453. PubMed ID: 30611963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study.
    Latif ZE; Solli KK; Opheim A; Kunoe N; Benth JŠ; Krajci P; Sharma-Haase K; Tanum L
    Am J Addict; 2019 Feb; 28(2):77-85. PubMed ID: 30701613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medication-assisted treatment for opioid use disorder within a 12-step based treatment center: Feasibility and initial results.
    Klein AA; Seppala MD
    J Subst Abuse Treat; 2019 Sep; 104():51-63. PubMed ID: 31370985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developing A Rapid Transfer from Opioid Full Agonist to Buprenorphine: "Ultrarapid Micro-Dosing" Proof of Concept.
    Azar P; Mathew N; Mahal D; Wong JSH; Westenberg JN; Schütz CG; Greenwald MK
    J Psychoactive Drugs; 2023; 55(1):94-101. PubMed ID: 35152847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does the Addition of Naloxone in Buprenorphine/Naloxone Affect Retention in Treatment in Opioid Replacement Therapy?: A Systematic Review and Meta-Analysis.
    Dalton K; Butt N
    J Addict Nurs; 2019; 30(4):254-260. PubMed ID: 31800516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary Analysis of Pain Outcomes in a Large Pragmatic Randomized Trial of Buprenorphine/Naloxone Versus Methadone for Opioid Use Disorder.
    Shulman M; Luo SX; Campbell ANC; Scodes J; Pavlicova M; Broffman A; Saxon AJ; Nunes EV
    J Addict Med; 2020; 14(5):e188-e194. PubMed ID: 32039934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic Disease Medication Adherence After Initiation of Buprenorphine for Opioid Use Disorder.
    Chang HY; Daubresse M; Saloner B; Alexander GC
    Med Care; 2019 Sep; 57(9):667-672. PubMed ID: 31404013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 36. A Descriptive analysis of urine drug screen results in patients with opioid use disorder managed in a primary care setting.
    Sobel HG; Warrington JS; Francis-Fath S; Crocker AM; Berger CA
    Addict Sci Clin Pract; 2021 Sep; 16(1):59. PubMed ID: 34593036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
    Soyka M; Hillemacher T
    Addiction; 2014 Jan; 109(1):88-9. PubMed ID: 24438113
    [No Abstract]   [Full Text] [Related]  

  • 38. Buprenorphine/Naloxone for Opioid Use Disorder Among Alaska Native and American Indian People.
    Lillie KM; Shaw J; Jansen KJ; Garrison MM
    J Addict Med; 2021 Jul-Aug 01; 15(4):297-302. PubMed ID: 33074852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pain is not associated with worse office-based buprenorphine treatment outcomes.
    Fox AD; Sohler NL; Starrels JL; Ning Y; Giovanniello A; Cunningham CO
    Subst Abus; 2012; 33(4):361-5. PubMed ID: 22989279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.